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Effect of Vision Therapy on Measures of Oculomotor Function 
in Patients Presenting with Post-Concussion Syndrome
Abstract
Oculomotor dysfunction is a common symptom of post-concussion syn-
drome	 (PCS).	 In	 this	 study,	 the	 efficacy	 of	 Vision	 Therapy	 (VT)	 for	 the	
treatment of PCS-related symptoms of the visual system was investigated 
retrospectively. Overall, 56 patients were selected, all of whom presented 
with clinical impairment of at least one measure of oculomotor function-
ing. Activities related to VT were wide-ranging and case-dependent, but all 
aimed	to	improve	one	of	the	five	main	areas	of	visual	function.	Following	
the completion of VT, all patients demonstrated statistically or clinically 
significant	 improvements,	as	defined	by	 the	use	of	Morgan’s	norms,	 in	at	
least one measure of oculomotor functioning related to PCS. In general, 
improvements in measures of oculomotor functioning were greatest for 
near point of convergence, vergence facility and accommodative facility. 
Patients who received 20 sessions of VT had improved and less variable 
outcomes than those who received 5-10 sessions of VT. In addition, VT im-
proved symptoms of visual discomfort in patients presenting with PCS. The 
results	of	this	retrospective	analysis	demonstrate	significant	improvements	
in measured outcomes for all patients who received VT, and support VT as 
a treatment option for symptoms of PCS.
INTRODUCTION
Mild traumatic brain injury (TBI), such as that sustained due to a blow 
to the head, violent shaking or movement of the head or body, can lead to 
symptoms of concussion.1 Following injury, symptoms of a concussion gen-
erally	manifest	 in	the	first	7-10	days	and	can	persist	for	up	to	one	year	or	
more. Symptoms of a concussion are referred to collectively as post-con-
cussion syndrome (PCS).1 Symptoms of PCS include, but are not limited to, 
headaches, dizziness, fatigue, noise and light sensitivity, and issues asso-
ciated with the visual system. In particular, between 11% and 54% of pa-
tients in cohort studies of soldiers or patients of auto accidents presenting 
with symptoms of TBI have been diagnosed with one or more oculomotor 
dysfunctions	including	convergence	insufficiency,	accommodative	insuffi-
ciency, impaired version movement, and minor ocular alignment issues.2–10 
In addition, 46% of adolescents presenting with symptoms of a concussion 
had more than one vision-related diagnosis such as accommodative disor-
der,	convergence	 insufficiency	or	saccadic	dysfunction.11 Convergence in-
sufficiency	is	a	prevalent	vision	disorder	characterized	by	reduced	fusional	
convergence amplitude and receded near point of convergence, which can 
manifest as blurred vision, eye strain and headaches when engaging in near 
work.12–14 Previous work has suggested that symptoms of convergence in-
sufficiency	and	related	oculomotor	issues	are	likely	due	to	excessive	con-
vergence compensation for large exophoric postures in near vision.15 
Optometric vision therapy (VT) has emerged as a promising treatment op-
tion for patients presenting with symptoms of PCS or TBI.4,5 For example, 
in a retrospective study, 90% of participants receiving VT for an acquired 
brain	injury	demonstrated	complete	or	significant	improvements	in	at	least	
one of the recorded symptoms of acquired brain injury, and these changes 
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persisted when measured 2 months or more following completion of VT.16 In addition, similar improvements in 
measures of oculomotor functioning have been observed in most patients receiving VT for PCS or TBI.4,5,17–20 Fur-
thermore, VT has been demonstrated to improve measures of concentration, memory and comprehension in pa-
tients presenting with symptoms of PCS or TBI.20	By	use	of	the	convergence	insufficiency	treatment	trial	symptom	
survey (CISS), Alvarez et al.21	demonstrated	significant	improvements	in	patients	presenting	with	convergence	in-
sufficiency	following	18	h	of	vergence	training,	and	their	scores	were	similar	to	those	in	control	patients.	In	addition,	
the work by Alvarez et al.21	further	supports	the	notion	that	convergence	insufficiency	is	due	to	significantly	reduced	
convergence peak velocity, and vergence training leads to increased functional activity. Furthermore, Scheiman 
and Wick.15	demonstrated	that	office-based	vergence	and	accommodative	therapy	with	home	practice	can	result	in	
sustained	improvements	in	symptoms	of	convergence	insufficiency.
Although there exists evidence to support VT in the treatment of PCS- or TBI-related symptoms, additional data to 
support a positive role for VT in the treatment of traumatic brain injury would be timely.4,22 Therefore, in this work, 
we	present	the	results	of	a	retrospective	analysis	of	the	efficacy	of	VT	treatment	for	improving	various	oculomotor	
functions in patients presenting with symptoms of PCS.
METHODS
Patients provided their express consent before treatment for oculomotor dysfunction was initiated.
PATIENT EVALUATION
Patients diagnosed with PCS by a physician were given a thorough oculo-visual assessment. Vision testing relevant 
to this study included assessments of near point of convergence (NPC), vergence facility (12 Base Out and 3 Base In), 
accommodative facility by use of + / - 2.00D lens power (age-dependent), stereopsis measures at near (40cm) and 
distance (6 metres) by use of Randot Stereopsis testing, King-Devick Saccadic Testing, positive fusional vergence 
ranges at near (40cm) and distance (6 metres), negative fusional vergence ranges at near (40cm) and distance (6 
metres) and completion of CISS before and one week following treatment. All tests were performed as described 
by Elliott.23 Patients presenting with nerve palsies, extraocular muscle restrictions, elevated intraocular pressure or 
gross	visual	field	loss	as	determined	by	confrontation	were	excluded	from	the	study.	
VISION THERAPY TREATMENT REGIMEN
Following assessment, the number of sessions required was selected on a per-patient basis based on best judgement, 
previous literature and occasionally by approval from 3rd-party payors.2,15,24 Vision therapy consisted of weekly one-
hour sessions at the clinic performed by trained vision therapists and prescribed daily sessions of 15 minutes at home. 
Activities	prescribed	were	wide-ranging	and	case-dependent,	but	all	aimed	to	improve	one	of	five	main	areas	of	visual	
function: central-peripheral visual integration (spatial awareness), eye teaming (converging and diverging), eye focus-
ing (accommodation), eye tracking (smooth pursuits and saccades), and motion processing (tracking of moving objects 
within a busy visual scene). The details of the procedures used throughout therapy have been described previously.15,25
STATISTICAL ANALYSIS
Patient data were collected between January 1, 2017, and December 31, 2017, from all patients receiving vision ther-
apy for PCS (n=56). Individual scores of the 56 patients were averaged across all measured outcomes and values 
before (pre-) and after (post-) VT intervention were compared. Patient outcomes pre- and post-VT were compared 
by use of the dependent t-test (p < 0.05). Endpoints that did not meet the assumptions of normality or equal vari-
ance were compared by use of the Wilcoxon signed rank test as suggested by Rosner et al.26 To assess the clinical 
significance	of	patient	outcomes,	measured	or	recorded	values	were	compared	with	the	relevant	literature,	namely	
Morgan’s table of norms.15
RESULTS
Data overview 
Overall, 56 patients were included in the retrospective analysis and descriptive statistics are presented in Table 1. 
Patients experienced a range of events resulting in the presence of PCS, including motor vehicle accidents in 38, 
sport-related injuries in 10 and falls in 8. Patient age ranged between 12 and 62 years (mean ± SD; 42.6 ± 13.8) and 
patients received between 5 and 20 sessions of VT (13.8 ± 4.70) to treat symptoms of PCS. The average patient pro-
gram	duration	(15.2	weeks)	was	greater	than	the	number	of	sessions	of	VT	(13.8	sessions)	and	reflects	the	impact	
of patient appointment cancellation or delays in treatment from week-to-week on program duration. In addition, 
patients generally began VT treatment one month following assessment.




functions (Table 2). All patients included in this study demonstrated improvement in at least one measure of ocu-
lomotor functioning. Forty-six patients presented with clinically impaired NPC and, following VT, 86% of patients 
demonstrated	clinically	relevant	improvements	(Table	2).	Fifty-five	patients	presented	with	clinically	impaired	ver-
gence facility (Table 2) and, following VT, all patients demonstrated improved vergence facility; this improvement 
was clinically relevant in 36 (65%). When assessed for accommodative facility, 20 of 22 patients presented clinically 
relevant	impairment	and,	following	treatment,	90%	of	patients	demonstrated	clinically	significant	improvements.	
When measured by use of the King-Devick Test, 43 patients presented clinically impaired saccadic movement and, 
following	treatment,	26	patients	(60%)	demonstrated	clinically	significant	improvements	(Table	2).	
Forty-six patients presented with clinically relevant impairment of stereopsis when tested at distance. All pa-
tients but 3 experienced average score improvements of 50%, and these improvements were clinically relevant in 
23 (50%). When stereopsis was assessed at near distances, 40 patients demonstrated clinically relevant impair-
ment. Following treatment, average improvements of 45% were observed, and 30 patients (75%) had clinically 
significant	outcomes.	Fifty-three	patients	had	CISS	symptom	survey	scores	greater	than	22.	Following	treatment,	
all	patients	showed	average	score	improvements	of	48%,	and	these	improvements	were	clinically	significant	in	
35 (66%) (Table 2).
Patient convergence and divergence test scores
Both positive and negative fusional vergence ranges (PFV/NFV) were assessed at distance (6 metres) and near 
(40cm). When PFV at distance was measured, 51 patients presented with clinically impaired convergence break. 
Forty-nine patients had an average improvement of 11D in positive fusional break scores, and these improvements 
were clinically relevant in 26 (53%). When assessed for PFV recovery at distance, 46 patients presented with 
clinically impaired scores. Following treatment, all but one patient had improved scores, and these improvements 
were	clinically	significant	in	32	(69%)	(Table	2).	When	NFV	at	distance	was	assessed,	52	patients	presented	with	
clinically relevant impairment when assessed for divergence break. Following treatment, 47 patients had an ob-
served	average	score	improvement	of	4.7	D,	and	this	improvement	was	clinically	significant	in	35	(67%).	When	
assessed for NFV recovery at distance, 42 patients presented with clinically relevant impairment. All but one 
patient	demonstrated	improvements	in	score	following	VT,	and	these	improvements	were	clinically	significant	
in 40 (95%) (Table 2). 
Improvements similar to those at distance were observed for fusional vergence ranges at near. Fifty patients pre-
sented with clinically impaired PFV break. Forty-nine patients had average improved scores of 19.6 D, and these 
improvements were clinically relevant in 46 (94%). When assessed for PFV recovery at near, 47 patients presented 
with clinically relevant impairment. Overall, patients saw an average improvement of 18.5 D, and these improve-
ments were clinically relevant in 42 (89%) (Table 2). When assessed for NFV ranges at near, 55 patients presented 
with	clinically	 relevant	deficits.	Fifty-three	patients	 saw	an	average	 improvement	of	 10.4	D,	 and	 these	 improve-
ments	were	clinically	significant	in	30	(55%).	When	assessed	for	NFV	recovery	at	near,	45	patients	presented	with	
clinically relevant impairment. All but one patient demonstrated an average improvement of 12 D following VT, and 
these	improvements	were	considered	clinically	significant	in	41	(91%)	(Table	2).	
Effect of treatment duration
Because patients received between 5 and 20 VT sessions, we wished to compare measures of oculomotor function-
ing among patient cohorts receiving 5-10, 12-17 or 20 sessions of VT (Table 3). In general, improvements in measures 
of oculomotor functioning were observed regardless of the duration of treatment. However, patients who received 
20 sessions demonstrated greater improvements in scores than patients who received 10 or less sessions of VT. 
Improvements in vergence facility, stereopsis at distance, and measures of PFV and NFV at both distance and near 
showed the greatest improvement with a longer treatment duration (Table 3). In addition, measured outcome im-
provements were compared among age groups, and no trend was observed. 
DISCUSSION
The effectiveness of VT in the treatment of PCS-related symptoms of the visual system was investigated retrospec-
tively. Overall, 56 patients were included in this study, all of whom presented with clinical impairment of at least 
one measure of oculomotor functioning (Table 1; Table 2). Following VT, all patients demonstrated statistically or 
clinically	significant	improvements	in	at	least	one	measure	of	oculomotor	functioning	related	to	PCS	(Table	2).	In	
general, improvements in measures of oculomotor functioning were greatest for NPC, vergence facility and accom-
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modative facility (Table 2). These results were similar to those of Ciuffreda et al.,16 who reported that, in multiple 
studies, 87-100% of patients with an acquired brain injury saw improvements in accommodative dysfunction fol-
lowing VT. More recently, Thiagarajan and Ciuffreda18	demonstrated	the	efficacy	of	VT	for	improving	amplitudes	of	
vergence and accommodation, accuracy of saccadic eye movements, and overall reading in patients with mild TBI.18 
Furthermore, improvements in NPC, PFV at near and distance, and CISS symptom scores were similar to those 
observed in children and a cohort with an age range similar to that in this study.22,24
Interestingly, patients who received 20 sessions of VT had improved and less-variable outcomes than those who 
received	5-10	sessions	of	VT	(Table	3).	These	results	are	similar	to	those	of	the	Convergence	Insufficiency	Treat-
ment Trial Study Group,24	which	observed	that	12	weeks	of	VT	sessions	was	insufficient	to	normalize	measures	of	
oculomotor functioning in children with mild TBI. However, it is important to note that, regardless of the program 
duration, measures of oculomotor functioning, such as convergence and accommodation, can be improved within 
as little as two to six weeks of VT.4,27 
Vision therapy was found to improve symptoms of visual discomfort in patients presenting with PCS, as demon-
strated by average improvements of 50% in CISS scores, similar to previous results reported by Scheiman and 
Wick15 (Table 2). However, although improvements in oculomotor functioning were apparent, no outcomes related 
to return-to-work or activities of daily living were recorded in this study, and this limits the interpretation of the re-
sults. Caution should be exercised in interpretation of these results as there is a tendency for measured oculomotor 
outcomes, especially near point of convergence, to improve over time in placebo groups.27 In addition, the effects of 





more, the present results suggest that longer treatment times (20 VT sessions) might improve measured outcomes 
compared to those in patients who receive 10 or less VT sessions; however, the impact of delayed VT treatment re-
mains	unclear.	Although	no	placebo	group	was	available	in	this	study,	the	results	demonstrate	significant	improve-
ments in measured outcomes for all patients receiving VT and support VT as a treatment option for PCS. l
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Table 1: Summary statistics of treatment regimen and descriptive statistics of patients receiving vision therapy treatments 
for post-concussion syndrome (n=56).
Measure Average Standard Deviation Range
Age 42.6 13.8 12 – 62
Months since injury 15.1 14.2 2 – 60
Delay in starting VT (months) 
following assessment
1.5 2 0 – 12
Sessions of VT 13.8 4.7 5 – 20
Duration of Program (weeks) 15.2 4.9 6 – 24
Table 2: Summary statistics of optometric data following vision therapy treatment for post-concussion syndrome (n=56).
Measure Pre VT Post VT Score  Improvement
avg std avg std avg std range
NPC (cm) 13.0 9.3 3.57* 1.94 65% 2 6.2 – 97%
Vergence Facility (cpm) 2.38 3.92 13.1* 3.18 83% 27 0 – 100%
Accomodative Facility – Binocular (cpm) δ 3.14 3.06 10.6* 1.87 71% 26 17- 100%
King Devick (s) 76.4 41.0 51.4* 18.3 27% 16 0 – 73%
Stereopsis- 40 cm (secs of arc) 79.8 40.6 42.6* 14.3 39% 23 0 – 85%
Stereopsis- 6 metres (secs of arc) 134 125 48.2* 12.8 41% 31 0 – 90%
CISS (Score) 38.2 11.42 20.0* 8.00 49% 14 23 – 100%
Measure Pre VT Post VT Score Improvement
avg std avg std avg std range
PFV Break -D (6m) 8.05 5.94 19.4* 7.43 11.4 7.4 0 – 30
PFV Recovery -D (6m) 4.36 4.86 14.8* 6.67 10.4 6.4 0 – 28
NFV Break -D (6m) 3.77 2.36 8.46* 2.98 4.7 3.3 0 – 16
NFV Recovery -D (6m) 1.09 2.51 5.96* 2.27 4.9 3 0 – 15
PFV Break -D (40cm) 11.4 7.25 29.6* 6.98 18.2 8.9 0 – 38
PFV Recovery -D (40cm) 4.46 6.16 21.3* 7.49 16.9 9.1 0 – 38
NFV Break -D (40cm) 11.1 5.99 21.4* 3.30 10.3 6.3 0 – 27
NFV Recovery D (40cm) 6.48 5.37 16.8* 3.45 10.3 6.2 -4 – 22
*Significant	improvement	in	score	(p	<	0.001). 
δn=22, average age of 28.4 ± 10.1
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Table 3: Summary statistics of patient score improvements following vision therapy treatments for post concussion syndrome 
grouped by number of VT sessions (n=56).
Number of VT Sessions 5-20 5-10 12-17 20
Count (n) 56 29 10 17
avg std avg std avg std avg std
Months since injury 15.1 14.2 14.3 13.2 14.9 18.6 16.4 13.7
Duration of program (weeks) 15.2 4.86 11.2 2.13 16.0 1.56 21.5 0.94
Percent Score Improvement
Measure avg std avg std avg std avg std
NPC (cm) 65% 20 67% 18 64% 25 62% 21
Vergence Facility (cpm) 83% 27 77% 32 83% 23 94% 12
Accomodative Facility (cpm) δ 71% 26 66% 27 85% 17 72% 31
King Devick (s) 27% 16 23% 16 30% 12 31% 19
Stereopsis- Near 39% 23 34% 22 54% 27 38% 20
Stereopsis- Dist 41% 31 29% 27 61% 33 50% 28
CISS (Score) 49% 14 50% 16 55% 14 46% 9
Score Improvement
Measure avg std avg std avg std avg std
PFV Break  D (6m) 11.4 7.42 10.8 8.08 10.0 5.25 13.1 7.36
PFV Recovery - D (6m) 10.4 6.44 10.3 7.43 9.80 4.57 10.9 5.81
NFV Break  D (40cm) 4.70 3.35 4.59 3.59 4.60 3.66 4.94 2.88
NFV Recovery- D (40cm) 4.88 3.03 5.10 3.45 3.60 2.84 5.24 2.25
PFV Break- D (40cm) 18.2 8.92 17.2 8.56 16.6 10.8 20.6 8.42
PFV Recovery- D (40cm)Near 16.9 9.13 15.9 9.71 16.4 9.65 18.8 7.95
NFV Break- D (40cm) 10.3 6.33 9.66 5.10 9.60 6.31 11.8 8.14
NFV Recovery- D (40cm) 10.3 6.17 9.93 5.08 8.90 7.34 11.8 7.17
δn=22, average age of 28.4 ± 10.1
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